EyePoint Pharmaceuticals, Inc. (EYPT) Earnings History
Annual and quarterly earnings data from 2003 to 2025
Loading earnings history...
EYPT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
EYPT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 93.4% | -776.0% | -739.4% |
| 2024 | 91.4% | -337.1% | -302.4% |
| 2023 | 89.9% | -163.1% | -153.8% |
| 2022 | 79.9% | -240.6% | -247.0% |
| 2021 | 77.9% | -149.6% | -158.1% |
Download Data
Export EYPT earnings history in CSV or JSON format
Free sign-in required to download data
EyePoint Pharmaceuticals, Inc. (EYPT) Earnings Overview
As of May 8, 2026, EyePoint Pharmaceuticals, Inc. (EYPT) reported trailing twelve-month net income of -$232M, reflecting -36.6% year-over-year growth. The company earned $-2.79 per diluted share over the past four quarters, with a net profit margin of -739.4%.
Looking at the long-term picture, EYPT's historical earnings data spans multiple years. The company achieved its highest annual net income of $9M in fiscal 2010.
EyePoint Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including OCUL (-$290M net income, -513.2% margin), RCKT (-$223M net income), ALDX (-$43M net income), EYPT has room to improve margins relative to the peer group. Compare EYPT vs OCUL →
EYPT Earnings vs Peers
Earnings metrics vs comparable public companies
EYPT Historical Earnings Data (2003–2025)
23 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$232M | -77.2% | -$243M | $-3.17 | -739.4% | -776.0% |
| 2024 | -$131M | -84.9% | -$146M | $-2.32 | -302.4% | -337.1% |
| 2023 | -$71M | +30.8% | -$75M | $-1.82 | -153.8% | -163.1% |
| 2022 | -$102M | -75.0% | -$100M | $-2.74 | -247.0% | -240.6% |
| 2021 | -$58M | -28.7% | -$55M | $-2.03 | -158.1% | -149.6% |
| 2020 | -$45M | +20.1% | -$37M | $-3.54 | -131.8% | -108.3% |
| 2019 | -$57M | -6.8% | -$48M | $-6.04 | -278.9% | -235.0% |
| 2018 | -$53M | -187.6% | -$26M | $-11.50 | -1795.7% | -887.3% |
| 2017 | -$18M | +14.2% | -$19M | $-5.23 | -245.2% | -246.4% |
| 2016 | -$22M | -439.5% | -$22M | $-6.81 | -1330.1% | -1344.1% |
See EYPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EYPT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EYPT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEYPT — Frequently Asked Questions
Quick answers to the most common questions about buying EYPT stock.
Is EYPT growing earnings?
EYPT EPS fell to $-2.79, with earnings declining -36.6%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-232M.
What are EYPT's profit margins?
EyePoint Pharmaceuticals, Inc. net margin is -739.4%, with operating margin at -776.0%. Below-average margins reflect competitive or cost pressures.
How consistent are EYPT's earnings?
EYPT earnings data spans 2003-2025. The declining earnings trend is -36.6% YoY. Historical data enables comparison across business cycles.